Phenox GmbH
http://www.phenox.net/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Phenox GmbH
Gain Therapeutics Navigates Market Fluctuations While Developing Parkinson’s Treatment
Gain Therapeutics aims to offer a disease-modifying treatment for Parkinson’s patients with GCase mutations. The company’s promising data and platform face competition from notable rivals.
Biopharma M&A Volume, Value Bounced Back Significantly In Q4
Acquisition activity in the biopharmaceutical sector saw a strong uptick in deal value and an exponential increase in total deal value during the fourth quarter, according to data from Evaluate.
AbbVie’s Parkinson’s Plans Back In The PINK With Mitokinin Buy
Just over six months after getting a complete response letter for its prodrug carbidopa and levodopa combination product, the US major has acquired Mitokinin and its selective PINK1 activator which could potentially be a disease-modifying treatment for Parkinson’s disease.
Dealmaking Quarterly Statistics, Q2 2022
During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.
Company Information
- Industry
-
Medical Devices
- Implantable Devices
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice